BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 26599054)

  • 1. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
    Tiepolt S; Patt M; Hoffmann KT; Schroeter ML; Sabri O; Barthel H
    J Alzheimers Dis; 2015; 47(3):539-43. PubMed ID: 26401690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.
    Caroli A; Prestia A; Wade S; Chen K; Ayutyanont N; Landau SM; Madison CM; Haense C; Herholz K; Reiman EM; Jagust WJ; Frisoni GB;
    Alzheimer Dis Assoc Disord; 2015; 29(2):101-9. PubMed ID: 25437302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.
    Kandel BM; Avants BB; Gee JC; Arnold SE; Wolk DA;
    J Alzheimers Dis; 2015; 46(4):901-12. PubMed ID: 25881908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Searching for Primary Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Multivariate Follow-Up Study.
    López ME; Turrero A; Cuesta P; López-Sanz D; Bruña R; Marcos A; Gil P; Yus M; Barabash A; Cabranes JA; Maestú F; Fernández A
    J Alzheimers Dis; 2016 Mar; 52(1):133-43. PubMed ID: 27060953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Löwe LC; Gaser C; Franke K;
    PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study.
    Inui Y; Ito K; Kato T;
    J Alzheimers Dis; 2017; 60(3):877-887. PubMed ID: 28922157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression.
    Teipel SJ; Kurth J; Krause B; Grothe MJ;
    Neuroimage Clin; 2015; 8():583-93. PubMed ID: 26199870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subtypes: Stratification Based on Imaging Biomarkers.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Alzheimers Dis; 2016 Apr; 52(4):1385-401. PubMed ID: 27079727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients.
    Choo IH; Ni R; Schöll M; Wall A; Almkvist O; Nordberg A
    J Alzheimers Dis; 2013; 33(4):929-39. PubMed ID: 23047371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.